Arvinas (ARVN)

• Market cap: $781M
• 1 day: -0.08%
• 5 days: 7.52%
• 1 month: -2.09%
• 3 months: 47.04%
• 6 months: 55.9%
• Year to date: -35.63%
• 1 year: -36.27%
• 5 years: -85.26%
• 10 years: -24.24%
• Sector: Healthcare
• Industry: Biotechnology

About: Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Employees: 430